How does RMD's Q3 2025 EPS forecast compare to past trends?
4/6/2025 06:30pm
ResMed's (RMD) Q3 2025 EPS forecast of $2.11 is significantly higher than the EPS of $1.49 reported for Q3 2023, indicating a strong recovery or growth in earnings compared to the previous year. This suggests that RMD's performance in the latest quarter is robust, potentially due to factors such as market conditions, company performance, or industry trends.
|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|RMD|RMD.N|ResMed|2023 Q1|2.8776978417266217|1.43|169|
|RMD|RMD.N|ResMed|2023 Q2|11.678832116788314|1.53|169|
|RMD|RMD.N|ResMed|2023 Q3|29.508196721311485|1.58|169|
|RMD|RMD.N|ResMed|2024 Q1|4.195804195804199|1.49|169|
|RMD|RMD.N|ResMed|2024 Q2|-7.189542483660137|1.42|169|
|RMD|RMD.N|ResMed|2024 Q3|29.113924050632907|2.04|169|
|RMD|RMD.N|ResMed|2025 Q1|41.610738255033546|2.11|169|
|RMD|RMD.N|ResMed|2025 Q2|64.7887323943662|2.34|169|